EMElena Morin

Elena Morin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Morin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Philippe Pradère

    RESTORE, Inserm U1301, CNRS 5070, Université de Toulouse, Université Toulouse III - Paul Sabatier, EFS, ENVT, France (L.P., M.V., P.V., J.-P.P.).

    2 shared publications
  • Aissette Baanannou

    Affiliation MDI Biological Laboratory, Kathryn W. Davis Center for Regenerative Biology and Aging, Bar Harbor, Maine, United States of America

    1 shared publication
  • Andrew P. Wojtovich

    Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA; Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA

    1 shared publication
  • Anna Mattout

    Department of Genetics, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

    1 shared publication
  • Annika Müller-Eigner

    Department of Anesthesiology and Perioperative, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA

    1 shared publication
  • Armelle Yart

    INSERM UMR 1048, Institute of Cardiovascular and Metabolic Diseases (I2MC), University of Toulouse Paul Sabatier, Toulouse, France

    1 shared publication

Latest Publications

  • Open Access

    The nuanced role of mitochondrial ROS in modulating aging and aging hallmarks

    by Annika Müller-Eigner, Elena Morin, Katherine S. Morton, Andrew P. Wojtovich


  • Open Access

    Zebrafish genetic model of neuromuscular degeneration associated with Atrogin-1 expression

    by Romain Menard, Elena Morin, Dexter Morse, Caroline Halluin, Marko Pende, Aissette Baanannou, Janelle Grendler, Heath Fuqua, Jijia Li, Laetitia Lancelot, et al.

    The degenerative loss of muscle associated with aging leading to muscular atrophy is called sarcopenia. Currently, practicing regular physical exercise is the only efficient way to delay sarcopenia onset. Identification of therapeutic targets to alleviate the symptoms of aging requires in vivo model organisms of accelerated muscle degeneration and atrophy. The zebrafish undergoes aging, with hallmarks including mitochondrial dysfunction, telomere shortening, and accumulation of senescent cells. However, zebrafish age slowly, and no specific zebrafish models of accelerated muscle atrophy associated with molecular events of aging are currently available. We have developed a new genetic tool to efficiently accelerate muscle-fiber degeneration and muscle-tissue atrophy in zebrafish larvae and adults. We used a gain-of-function strategy with a molecule that has been shown to be necessary and sufficient to induce muscle atrophy and a sarcopenia phenotype in mammals: Atrogin-1 (also named Fbxo32). We report the generation, validation, and characterization of a zebrafish genetic model of accelerated neuromuscular atrophy, the atrofish. We demonstrated that Atrogin-1 expression specifically in skeletal muscle tissue induces a muscle atrophic phenotype associated with locomotion dysfunction in both larvae and adult fish. We identified degradation of the myosin light chain as an event occurring prior to muscle-fiber degeneration. Biological processes associated with muscle aging such as proteolysis, inflammation, stress response, extracellular matrix (ECM) remodeling, and apoptosis are upregulated in the atrofish. Surprisingly, we observed a strong correlation between muscle-fiber degeneration and reduced numbers of neuromuscular junctions in the peripheral nervous system, as well as neuronal cell bodies in the spinal cord, suggesting that muscle atrophy could underly a neurodegenerative phenotype in the central nervous system. Finally, while atrofish larvae can recover locomotive functions, adult atrofish have impaired regenerative capacities, as is observed in mammals during muscle aging. In the future, the atrofish could serve as a platform for testing molecules aimed at treating or alleviating the symptoms of muscle aging, thereby opening new therapeutic avenues in the fight against sarcopenia.


  • EMito-Metrix enables automated evaluation of mitochondrial morphology across species

    by Eléna Morin, Emmanuel Doumard, Lisa M. Hartnell, Beñat Salegi Ansa, Jean-Philippe Leduc-Gaudet, Aurélie Quillien, Jean Nakhle, Séverine Ethuin, Dominique Goudounèche, Bruno Payré, et al.